Member Info for Dazpink

Intresting article last month about puretech, Eric Elenko Says PureTech Turned $18.5 Million Into $1.1 Billion by Fixing Big Pharma's Castoffs

https://finance.biggo.com/news/fe8c9bd942c4ed51

CEO Robert Lyne will be desperate to change things, he took on the role permanently in December 2025, he is facing significant operational pressure to steer a structural turnaround. After stepping into the role permanently following a wave of executive departures, he is tasked with addressing a depressed stock valuation that heavily lags behind its internal earnings progress.

Spin-outs and Funding Milestones

Financing Celea Therapeutics: Lyne's most immediate priority is securing independent external funding to spin out Celea Therapeutics, which houses the Phase 3-ready lung disease drug deupirfenidone. Closing this deal will sharply lower PureTech's remaining cash run rate

Funding Gallop Oncology: Concurrently, he is under pressure to lock in separate financing for Gallop Oncology to advance its leukemia therapeutic pipeline, LYT-200, without adding further financial stress to the parent firm

Potential Capital Returns: To combat this shareholder fatigue, Lyne has noted that once the Celea and Gallop spin-outs are fully financed, the board intends to evaluate direct capital returns to shareholders to restore confidence and boost the stock price

Dallo, I think its only because of the hub and spoke model and the complexity of puretech, I also believe that the timing hasn’t been right, offer was to low knowing what is in the pipeline.

Patience is key especially when we are this close to seeing the price being double if not treble based on funding and new data that is expected towards the end of this year

£1.60 no way, wake up see what is now changing in the pharma landscape, ie a massive shift toward cell and gene therapies, Oncology & Immunotherapy.

Could you imagine the nightmares investors would have had exiting any biotech startup after recent takeovers

Major acquisitions include Eli Lilly's $3.8 billion triple-buyout (Curevo, LimmaTech, and Vaccine Co.) to enter infectious diseases, and Chiesi's takeover of KalVista Pharma for rare diseases

Peter may have done more for Hemo than many people give him credit for, he has over 30 years of corporate finance and venture capital experience, he may not be running the science but will be actively involved in getting a good deal with Eli Lilly or another big pharma in the near future.

I don’t believe that he is getting options for doing nothing

300,000 shares each to the founders, Vlad and his wife (COO)and 2 other members of the board ( Chairman and FA isnt excessive, look at what Elon Musk, Jeff Bezos and many others held early on in the companies start up.

The exercise price of £8 which expires on 29 May 2031 is also well thought out.

This timing for them is good and us, they will know that things are moving quickly in this sector now and will be wanting to reach milestones very quickly to allow them to benefit from this grant of options.

I don’t have a problem with this as we all benefit in the long run, we may see things move more quickly now this has been revealed.

As per results 29th April 2026 Robert Lyne, Chief Executive Officer of PureTech, said:

I’m pleased to note that Celea has secured sufficient non-binding commitments from external investors, in addition to participation from PureTech, such that the fundraising is substantially complete, subject to

continued negotiations.

Whilst mindful of macro factors, Celea is targeting to close the financing by early in the third quarter of 2026. The financing is intended to support the Phase 3 SURPASS-IPF trial, which Celea expects to

commence in close proximity to closing the financing.

Gallop intends to pursue third-party capital to support a potentially registration-enabling trial in R/R

HR-MDS, with

the round targeted to close in the first quarter of 2027.

Tang Capital Management, LLC, founded by Kevin C. Tang, is one of the largest institutional investors in biotherapeutics company PureTech Health. The firm—which includes Tang Capital Partners, LP and Tang Capital Partners International, LP—owns over \(5\%\) of PureTech Health's total voting rights

Maybe time for them to increase their holding ?

Gallop oncology

From an investment perspective, LYT-200 is the standout crown jewel of PureTech Health’s internal pipeline.

Market Opportunity and Competitive MoatHigh-Value Target Market: The drug targets Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) and High-Risk Myelodysplastic Syndrome (HR-MDS). Because late-stage AML has a horrific survival outlook (under 3 months), any drug extending life to 13.2 months commands premium, multi-billion-dollar oncology pricing.The Galectin-9 First-Mover Advantage: LYT-200 is a first-in-class antibody targeting galectin-9. It faces virtually no direct competition for this specific checkpoint path, giving it a strong intellectual property moat.Registration Potential: In April 2026, PureTech finalized its Phase 1b data and selected its Phase 2 dose (12 mg/kg). They are actively engaging with the FDA to map out a trial framework designed for accelerated approval/registration

Gallop oncology

Key Catalysts to Watch if you are timing or evaluating a position, the critical value-inflection events for LYT-200 over the next 12 to 18 months include:FDA Phase 2 Protocol Agreement: Official guidance from the FDA on whether the upcoming Phase 2 trial can serve as a pivotal registrational study.Gallop Oncology Spin-out/Funding: A potential external venture capital raise or standalone IPO for Gallop Oncology to assign a direct, transparent market valuation to LYT-200.Big Pharma Partnership: A licensing deal or co-development partnership for the solid tumor (head and neck cancer) indications, which would inject non-dilutive milestones and validation into the company

The wait will be worth it, I am frustrated as everyone, I strongly belive this will bounce back big with Celea then you add in Seaport and Gallop

Key Clinical Highlights Phase 2b ELEVATE Trial: In Phase 2b clinical trials, deupirfenidone demonstrated the ability to stabilize lung function decline in patients with IPF over a 26-week period.Improved Tolerability: A pharmacokinetic crossover study showed that deupirfenidone resulted in roughly 50% fewer gastrointestinal adverse events (like nausea and vomiting) compared to standard pirfenidone.Designations: The drug has received Orphan Drug Designation from both the U.S. FDA and the European Commission for the treatment of IPF

Agree with AI

Celea Therapeutics will add substantial long-term economic and strategic value to PureTech Health (LSE: PRTC) by lowering PureTech's cash burn and providing an estimated \(\$1\) billion to \(\$1.5\) billion in post-financing valuation upside upon the commercial success or potential sale of its lead drug, deupirfenidone.The exact value will depend on how the upcoming Phase 3 trials unfold and the final terms of external financing, but PureTech stands to benefit through the following key avenues:Lowered Cash Burn: By spinning off the respiratory program into the founded entity Celea Therapeutics and utilizing external financing for the costly Phase 3 SURPASS-IPF study, PureTech effectively offloads major ongoing research and development expenses.Retained Equity & Upside: PureTech historically retains significant equity stakes and royalties in its founded entities. Because Celea successfully finalized a syndicated funding round with external investors, PureTech maintains a large portion of the potential future economic value without the direct financial weight of the trial.Blockbuster Drug Potential: Deupirfenidone (LYT-100) is a Phase 3-ready treatment for Idiopathic Pulmonary Fibrosis (IPF) that previously yielded compelling Phase 2b data. Because the IPF market is dominated by older therapies whose patents have expired or are at risk, a successful commercial rollout could yield hundreds of millions in peak annual sales.

Hope is no delays to puretech presentation regarding early Q3 RNS for Celea therapeutics with funding and official launch of phase 3 for Deupirfenidone

This will be a very important milestone

Large buy, nice to see

What we need is the FDA to grant hemo a voucher under the Priority Voucher Program or FDA Commissioner’s National Priority Voucher (CNPV) pilot program.

This drastically shortens review times for critical drugs to 1–2 months, compared to the standard 10–12 months.

Could you imagine what the share price would be if hemo were given this voucher, companies can sell them for $150-200 million so that would be added to the market cap if it happened

From AI, you maybe right ThetaDecay but I am hoping for something unexpected to get Puretech moving upwards

Based on current FDA, as of mid-2026, LYT-100 (deupirfenidone) is a strong candidate for the FDA Commissioner’s National Priority Voucher (CNPV) pilot program, rather than the traditional, transferrable Rare Pediatric Disease Priority Review Voucher (PRV) program

What we need is the FDA to grant Puretech a voucher under the Priority Voucher Program which was last introduced last June.

Robert Lyne and his team hopefully are able to pull a few strings , this drastically shortens review times for critical drugs to 1–2 months, compared to the standard 10–12 months.

Could you imagine what the share price would be if phase 3 LYT - 100 were given this voucher

Dallo, don’t worry Puretech will be bought out if the shareprice remains stagnant for the remaing part of 2026

Soon be £5 levels

Agree, I looked for evidence that it had submitted form S-1 but couldnt find anything. AI gave the responce to my question, would Celea therapeutics go public ipo to raise funds

Puretech strategy is to create independent companies (entities) with a senior management team, spin out its entities to external investors via capital sell off, allowing PureTech to retain a meaningful equity stake then go to IPO to raise more funds that benefit both companies

Lets see how this plays out over the next 3 months, I am holding on to my shares as the analyst forcast for Puretech is over £5 with a strong buy, these analysts may know more about what lies ahead